TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02962492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide/Exenatide extended release
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide/Exenatide extended release
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Study: NCT04087993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucoferron
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral administration
Study: NCT05576142

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral examination
Description: Patients underwent oral examination with the recording of DMFT, PSR, PI and presence/absence of mouth breathing.
Study: NCT02929589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Medication
Description: 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen + Opioid medication
Description: ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
Study: NCT03190993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Sweetened Solid Treatment
Description: Consume Sugar Sweetened Solid Treatment (product) daily.
Study: NCT00946088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene glycol&hydrogenated vegetable oil.
Description: Placebo Comparator: Polyethylene glycol 400 distearate \& hydrogenated vegetable oil per vagina qhs.
Study: NCT01882088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucofalk
Description: Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
Study: NCT00999271

Intervention type: OTHER
Intervention: Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)
Description: two different dosages:~* 0.8 pmol/kg/min~* 1.5 pmol/kg/min for 300 minutes
Study: NCT00977340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal Treatment
Description: Imagery Rehearsal Therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: confrontation
Description: Confrontation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: imagination
Description: Imagination
Study: NCT03490942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution is a non-active formulation containing excipients only.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution is a non-active formulation containing excipients only.
Study: NCT03190993

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Sweetened Beverage Treatment
Description: Consume Sugar Sweetened Beverage Treatment (product) daily.
Study: NCT01790984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar low starch diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar low starch diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar high starch diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sugar high starch diet
Study: NCT04502654

Intervention type: DEVICE
Intervention: Actiwatch 2 (Philips Respironics, Murrysville, USA)
Description: Actiwatch 2 is an unobtrusive, waterproof, light sensor and wrist-worn device (weight 16.0g, size 4.3 cm\* 2.3 cm\* 1.0 cm), containing a tri-axial accelerometer able to records a digitally integrated measure of gross motor activity (a piezoelectric sensor to detect vertical accelerations at the wrist between 0.5 and 2.0 g with a frequency response range between 0.35-7.5 Hz). Activity counts from the device reflect the peak acceleration detected over each epoch and are used in determining sleep and wake intervals, which can be used to rest-activity patterns, quality of physical activity and sleep for 15-60 seconds/ epoch, 24 hours/ day, 2 weeks.
Study: NCT04083885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants will be provided with a virtual reality training program, personalized with respect to their abilities, endurance, needs and treatment goals. They will be trained to use the program and it will be installed in their home or provided at their long-term care facility. Participants will be suggested to perform VR 3-5 times a week for 8 weeks. Sessions will be 20-30 minutes long, depending on tolerance.
Study: NCT00213954

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guidance with echography
Description: Locoregional anesthesia with or without ultrasound guidance practice

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guidance with echography
Description: Locoregional anesthesia with or without ultrasound guidance practice

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guidance with echography
Description: Locoregional anesthesia with or without ultrasound guidance practice

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasound-guidance with echography
Description: Locoregional anesthesia with or without ultrasound guidance practice
Study: NCT00585091

Intervention type: DRUG
Group type: OTHER
Intervention: phenylephrine
Description: All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
Study: NCT04264299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T tube drainage
Description: closure of common bile duct over T tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T tube drainage
Description: closure of common bile duct over T tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary closure
Description: Primary closure of common bile duct

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure
Description: Primary closure of common bile duct

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antegrade stenting
Description: Closure of common bile duct over antegrade plastic biliary stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Antegrade stenting
Description: Closure of common bile duct over antegrade plastic biliary stent
Study: NCT02304575

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory.

Intervention type: OTHER
Intervention: Hormonal Function measurement
Description: Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.

Intervention type: OTHER
Intervention: Hormonal Function measurement
Description: Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.

Intervention type: OTHER
Intervention: Hormonal Function measurement
Description: Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
Study: NCT01472588

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP lifestyle intervention-Community Health Coach (CHWs)
Description: Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DPP Lifestyle intervention--health professionals/(PHCs)
Description: Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.

Intervention type: OTHER
Group type: OTHER
Intervention: Self Help
Description: Public education/information booklet on weight management.
Study: NCT01421979

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink, Taurine, Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink, Taurine, Caffeine
Study: NCT02862665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iron isomaltoside 1000 (Monofer®)
Description: The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 100 ml
Description: The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
Study: NCT03839004

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated approach to pregnancy
Description: Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
Study: NCT02549326

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Study: NCT00711776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New formulation
Description: New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New formulation
Description: New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New formulation
Description: New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current formulation
Description: Current formulation of Aciclovir Cream 5% in Japan
Study: NCT02549326

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01729078

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
Study: NCT00390871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT04287660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
Description: * clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function.
Study: NCT01966120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-200 ALA gel
Description: BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BF-200 ALA gel
Description: The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy with BF-RhodoLED
Description: After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
Study: NCT04548895

Intervention type: DEVICE
Intervention: Observational measurement of biometric data. No change to health care provided.
Description: Emfit devices will be installed once after enrollment under each participant's mattress and left to record automatically without further intervention. The participants will wear their Biostrap wristbands consistently, ideally 24 hours a day, 7 days a week, for 2 months.~A virus panel will be upon enrollment (baseline) and then every two weeks (± 3 days, or on the closest convenient sampling day if the LTCF is testing all residents on the same day) for a maximum of 5 times during the two-month period. Using polymerase chain reaction or next generation sequencing, the virus panel will detect COVID-19 and 12 other common respiratory viruses that may cause similar symptoms and similar biometric signatures. These include influenza A and B, parainfluenza types 1 through 4, respiratory syncytial virus, non-COVID coronavirus, rhinovirus, adenovirus, bocavirus and metapneumovirus.
Study: NCT01966120

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic therapy with BF-RhodoLED
Description: After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
Study: NCT02482688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A New Rehabilitation Treatment following Stroke
Description: A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
Study: NCT02807766

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavior modification
Description: Each group has 30 subjects and experiences six months' training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior modification and sensory integration training
Description: Each group has 30 subjects and experiences six months' training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior modification and applied behavioral analysis
Description: Each group has 30 subjects and experiences six months' training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior modification and TEACCH
Description: Each group has 30 subjects and experiences six months' training.
Study: NCT02482688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A New Rehabilitation Treatment following Stroke
Description: A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A New Rehabilitation Treatment following Stroke
Description: A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A New Rehabilitation Treatment following Stroke
Description: A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
Study: NCT01775111

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cognitive Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength Training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FortiFit
Study: NCT00711776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current formulation
Description: Current formulation of Aciclovir Cream 5% in Japan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current formulation
Description: Current formulation of Aciclovir Cream 5% in Japan
Study: NCT01225198

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Vitamin/Mineral Supplement
Description: A broad-spectrum vitamin/mineral supplement designed for children and adults with autism

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid Placebo
Description: The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
Study: NCT04674215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Turning in Bed
Description: Preoperative Turning in Bed Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobilization
Description: Preoperative Mobilization Training

Intervention type: OTHER
Group type: OTHER
Intervention: information
Description: Routine Clinical Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information
Description: Routine Clinical Care